key: cord-0846355-71oczde6 authors: Cacciavillani, Mario; Salvalaggio, Alessandro; Briani, Chiara title: Pure sensory neuralgic amyotrophy in COVID‐19 infection date: 2020-10-01 journal: Muscle Nerve DOI: 10.1002/mus.27083 sha: 0a3333b78f9c6ca9ff655c16eede50747a4a9282 doc_id: 846355 cord_uid: 71oczde6 nan We read with great interest the case report on neuralgic amyotrophy following infection with SARS-CoV-2. 1 Respiratory symptoms are the primary manifestations of SARS-Cov-2 infection. Reports of several neurologic manifestations have most commonly involved the central nervous system. 2 Besides olfactory dysfunction, peripheral nervous system involvement has been reported primarily as Guillain-Barré syndrome. 3 We report pure sensory neuralgic amyotrophy in a patient with COVID- 19. An otherwise healthy 52-year-old man was admitted to the hospital for a pneumonia and tested positive for COVID-19 RNA by naso-pharyngeal swab. He was treated with hydroxychloroquine, antibiotics and oxygen and was discharged after five days. A week after the discharge, the patient developed excruciating pain in the left wrist and upper limb in the distribution of the lateral antebrachial cutaneous nerve followed shortly thereafter by hypoesthesia and dysesthesia in the same distribution. At onset, the pain was rated by the patient as 10/10 and was treated with acetaminophen with minimal relief. It gradually decreased and eventually resolved after two weeks. The patient noted no weakness and no other areas of pain or sensory symptoms. The neurological examination revealed normal strength, normal sensation except as noted, and normal reflexes. Electrodiagnostic testing performed five weeks after symptom onset showed a reduced sensory nerve action potential amplitude of the left lateral antebrachial cutaneous nerve. No other abnormalities were detected on nerve conduction study (Table 1) . Needle electromyography of the This article is protected by copyright. All rights reserved. left deltoid, biceps brachii, triceps brachii, brachioradialis, extensor digitorum communis, flexor digitorum superficialis and first interosseous muscles was normal. Ultrasound evaluations of the left median, ulnar, radial, posterior interosseus and musculocutaneous nerves were unremarkable along their explorable courses. A diagnosis of pure sensory neuralgic amyotrophy was made. Six weeks after the onset, hypoesthesia and dysesthesias persisted. Pure sensory involvement is a possible presentation of neuralgic amyotrophy. 4,5 Antecedent or concomitant infections are considered as possible triggers of an immune-mediated pathophysiologic mechanism. 6 Notably, in the present report diagnosis was delayed because the lockdown measures prevented a timely evaluation. The present report, which adds to the one described by Siepmann et al. 1 broadens the neurological spectrum of COVID-19 infection and suggests that this virus may be among those associated with neuralgic amyotrophy. This article is protected by copyright. All rights reserved. Neuralgic amyotrophy following infection with SARS-CoV-2 Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease This article is protected by copyright Online ahead of print COVID-19-Associated Guillain-Barre Syndrome: The Early Pandemic Experience Isolated sensory manifestations in neuralgic amyotrophy: report of eight cases Neuralgic amyotrophy: An update on diagnosis, pathophysiology, and treatment Ultrasound of peripheral nerves in neuralgic amyotrophy